Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis

Modern Rheumatology

Volumn 27, Issue 3, 2017, Pages 529-532

  Iwai, Atsuko ^a,c   Naniwa, Taio ^a,b   Tamechika, Shinya ^a,b   Maeda, Shinji ^a,b  

^a NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

^b Allergy and Clinical Immunology ^*  (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Cyclophosphamide; Pericarditis; Systemic lupus erythematosus; Tocilizumab

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; HAPTOGLOBIN; PREDNISOLONE; TACROLIMUS; TOCILIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTICLE; CASE REPORT; CHRONIC GASTRITIS; COLON POLYP; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ECHOGRAPHY; ERYTHEMA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GLOMERULONEPHRITIS; HAIR LOSS; HEMATURIA; HUMAN; HUMAN TISSUE; HYPOCOMPLEMENTEMIA; KERATOCONJUNCTIVITIS SICCA; LEG EDEMA; LOW DRUG DOSE; PANCYTOPENIA; PERICARDITIS; PHOTOSENSITIVITY; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROTEINURIA; SJOEGREN SYNDROME; STOMACH BIOPSY; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VOMITING; WEIGHT REDUCTION; XERODERMA; COMPLICATION; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CYCLOPHOSPHAMIDE; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PERICARDITIS; REMISSION INDUCTION;

EID: 85018757120     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.990409     Document Type: Article

References (11)

1. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus. 2005;14(1):13–8.
2. Theofilopoulos AN, Gonzalez-Quintial R, Lawson BR, Koh YT, Stern ME, Kono DH, et al. Sensors of the innate immune system:their link to rheumatic diseases. Nat Rev Rheumatol. 2010;6(3):146–56.
3. Grech P, Khamashta M. Targeted therapies in systemic lupus erythematosus. Lupus. 2013;22(10):978–86.
4. Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013; 65(10):2661–71.
5. Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CG. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol. 1992;90(1):106–10.
6. Lambotte O, Khellaf M, Harmouche H, Bader-Meunier B, Manceron V, Goujard C, et al. Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine (Baltimore). 2006;85(3):169–82.
7. Takahashi N, Naniwa T, Banno S. Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol. 2008;18(1):72–75.
8. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus:data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010; 62(2):542–52.
9. Kamata Y, Minota S. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep. 2012;2012. pii:bcr2012007834.
10. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48(6):1521–9.
11. van Vollenhoven R, Aranow C, Rovin B, Wagner C, Zhou B, Gordon R, et al. A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of sirukumab in patients with active lupus nephritis. Ann Rheum Dis. 2014;73 (Suppl 2):78.